Nonsteroidal Anti-Inflammatory Drugs (Nsaids)

NSAIDs should not be administered prior to or concomitantly with high-dose methotrexate. Concomitant administration has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and gastrointestinal toxicity.

NSAIDs may result in deterioration of renal function and loss of antihypertensive effect with benazepril, especially in elderly or volume-depleted patients.

NSAIDs may deteriorate renal function, cause acute renal failure, and attenuate antihypertensive effect of olmesartan. Monitor renal function periodically.

Aspirin increases risk of peptic ulceration and bleeding with additive effects.

Co-administration may result in deterioration of renal function, including possible acute renal failure, especially in elderly, volume-depleted, or renally compromised patients. NSAIDs may attenuate antihypertensive effect.

Coadministration increases the risk of gastrointestinal bleeding.

Increases risk of gastrointestinal bleeding when coadministered with clopidogrel.

Concomitant use with corticosteroids increases risk of gastrointestinal side effects.

May result in deterioration of renal function, including possible acute renal failure, especially in elderly, volume-depleted, or renally compromised patients. May diminish antihypertensive effect.

NSAIDs may reduce antihypertensive effect and cause severe hyperkalemia in patients with impaired renal function. Monitor blood pressure and serum potassium.

Increased risk of renal impairment and acute renal failure, especially in elderly or volume-depleted patients. Reduced antihypertensive effects. Monitor renal function periodically.

NSAIDs can reduce diuretic and antihypertensive effects, and may cause renal impairment including acute renal failure, especially in elderly or volume-depleted patients.

Concomitant administration may increase the risk of CNS stimulation and convulsive seizures.

NSAIDs may increase risk of CNS stimulation and convulsive seizures when combined with levofloxacin.

Co-administration may result in deterioration of renal function, including possible acute renal failure, especially in elderly patients, those volume-depleted, or with compromised renal function. NSAIDs may also attenuate the antihypertensive effect.

NSAIDs decrease renal blood flow, resulting in decreased renal clearance and increased serum lithium concentrations.

NSAIDs decrease renal blood flow, resulting in decreased renal clearance and increased serum lithium concentrations.

Risk of deterioration of renal function including possible acute renal failure, and reduced diuretic, natriuretic, and antihypertensive effects. Monitor renal function periodically.

NSAIDs may increase methotrexate plasma concentrations, increasing risk of severe adverse reactions.

NSAIDs may result in deterioration of renal function, including acute renal failure, especially in elderly, volume-depleted, or renally compromised patients. NSAIDs may also attenuate antihypertensive effect.

Concomitant use with NSAIDs may increase risk of CNS stimulation and convulsions.

Concomitant NSAIDs with ofloxacin may increase risk of CNS stimulation and convulsive seizures.

NSAIDs may lead to increased risk of renal impairment and loss of antihypertensive effect. In elderly, volume-depleted, or renal-compromised patients, may result in deterioration of renal function including acute renal failure.

NSAIDs may reduce diuretic, natriuretic, and antihypertensive effects; increased risk of renal toxicity and acute renal failure, particularly in elderly, volume-depleted, or renal-compromised patients.

NSAIDs may produce potassium retention by reducing renal prostaglandin E synthesis and impairing the renin-angiotensin system. Monitor for hyperkalemia.

May produce potassium retention; closely monitor potassium levels during concomitant use.

Coadministration may increase risk of adverse reactions. Avoid coadministration; if unavoidable, monitor for increased risk of adverse reactions.

May result in deterioration of renal function including possible acute renal failure in elderly, volume-depleted, or renal-compromised patients. May attenuate antihypertensive effect.

NSAIDs may result in deterioration of renal function, including possible acute renal failure, and may attenuate the antihypertensive effect of ARBs. NSAIDs reduce diuretic, natriuretic, and antihypertensive effects.

NSAIDs may result in deterioration of renal function including possible acute renal failure, especially in elderly, volume-depleted, or renal-compromised patients. May attenuate antihypertensive effect.

Blunting of the antihypertensive effect of acebutolol has been reported.

NSAID use is associated with gastrointestinal irritation; caution should be used during concomitant use with alendronate sodium.

NSAIDs are associated with gastrointestinal irritation; caution should be used during concomitant use with this medication.

Can reduce diuretic, natriuretic, and antihypertensive effects of amiloride HCl. Patient should be monitored to determine if desired diuretic effect is achieved.

NSAIAs may reduce diuretic, natriuretic, and antihypertensive effects. Patient should be observed closely to determine if desired diuretic effect is obtained.

NSAIDs can reduce the diuretic, natriuretic, and antihypertensive effects of chlorothiazide sodium. Patient should be closely observed to determine if desired diuretic effect is obtained.

Decline in GFR or tubular secretion may impair digoxin excretion. Individualize digoxin dosage and monitor.

NSAIDs may reduce the diuretic, natriuretic, and antihypertensive effects of ethacrynate sodium. Patient should be closely observed to ensure desired diuretic effect.

NSAIAs may reduce the diuretic, natriuretic, and antihypertensive effects of ethacrynic acid; patient should be observed closely.

NSAIDs may reduce diuretic and antihypertensive effects of fosinopril sodium and hydrochlorothiazide; effects not fully studied.

May potentiate hypoglycemic action of glyburide. Close observation for hypoglycemia recommended.

Highly protein-bound; may increase glucose-lowering effect of glimepiride, increasing susceptibility to hypoglycemia.

NSAIDs may potentiate hypoglycemic action of glipizide. Patient should be observed closely for hypoglycemia when initiated or withdrawn.

NSAIDs may potentiate the hypoglycemic action of glipizide. Patient should be observed closely for hypoglycemia.

NSAIAs can reduce the diuretic, natriuretic, and antihypertensive effects of hydrochlorothiazide; close patient monitoring is recommended.

Caution should be exercised with concomitant use of NSAIDs and ibandronate as both are associated with gastrointestinal irritation.

May alter T4 and T3 serum transport.

Fenamates may cause protein binding site displacement of thyroid hormones. Monitor thyroid hormone parameters.

Concurrent use may increase risk of nephrotoxicity. Monitor patients for changes in renal function and mesalamine-related adverse reactions.

Concomitant use with NSAIDs increases risk of gastrointestinal side effects.

May decrease the antihypertensive effects of metolazone.

NSAIDs may reduce the diuretic, natriuretic, and antihypertensive effects of hydrochlorothiazide.

Concomitant use may increase risks of CNS stimulation and convulsions.

NSAIDs with moxifloxacin may increase risks of CNS stimulation and convulsions.

May potentiate the risk of bleeding when combined with olanzapine and fluoxetine.

Concurrent use may increase risk of nephrotoxicity. Monitor patients for changes in renal function and mesalamine-related adverse reactions.

NSAIDs increase risk of fluid and electrolyte abnormalities when used with this drug combination. Use caution and consider additional patient evaluations.

Chronic coadministration may increase the risk of bleeding.

Chronic coadministration of prasugrel and NSAIDs may increase the risk of bleeding.

NSAIDs may attenuate the antihypertensive effect of propranolol. Monitor blood pressure.

NSAID use was studied in patients; upper gastrointestinal adverse experience incidence was similar between placebo and risedronate-treated patients. Monitor for GI effects.

Monitor for signs of worsening renal function. Increased risk of kidney injury, especially in patients with volume depletion or impaired kidney function.

NSAIDs may reduce diuretic, natriuretic, and antihypertensive effects of spironolactone. Monitor closely for desired diuretic effect.

Blunting of the antihypertensive effect of timolol; patients should be carefully observed to confirm desired therapeutic effect.

Caution advised when administering NSAIDs with triamterene and hydrochlorothiazide due to risk of acute renal failure.

Potentially nephrotoxic drugs; caution indicated when used with zoledronic acid due to increased risk of renal impairment.

No dose adjustment needed when co-administered with montelukast sodium.

No dose adjustment needed when co-administered with montelukast sodium.